InstalabLoading...
InstalabLoading...
If you eat fish regularly or take an omega-3 supplement, you probably assume your levels are fine. They might not be. People vary enormously in how they digest and absorb omega-3 fats, so what you swallow does not reliably predict what reaches your cells. OmegaCheck gives you the actual number.
That number carries real weight. In a study of about 2,500 adults followed for over seven years, those with the highest omega-3 blood levels had roughly 34% lower risk of dying from any cause and 39% lower risk of a new cardiovascular event, compared to those with the lowest levels. The effect held after adjusting for multiple standard risk factors including cholesterol, blood pressure, and smoking. When the researchers modeled omega-3 levels alongside total cholesterol, omega-3 remained significantly linked to outcomes while total cholesterol did not.
OmegaCheck (sometimes written as Omega Check) is a whole-blood test that quantifies your combined levels of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), the two omega-3 fatty acids most strongly linked to health outcomes. These are the same fats found in fatty fish, fish oil, and algae supplements.
Most of the large outcome studies in this field measured a closely related metric called the Omega-3 Index, which quantifies EPA and DHA specifically in red blood cell membranes. Because red blood cells live for about 120 days, the Omega-3 Index reflects your average omega-3 status over the past two to three months rather than what you ate yesterday. OmegaCheck uses whole blood rather than isolated red blood cells, but both measurements track the same underlying biology. The risk thresholds established for the Omega-3 Index provide the best available framework for interpreting your OmegaCheck result, though your lab's reported scale may differ slightly from the percentages used in the research described below.
The connection between omega-3 blood levels and heart disease is one of the most consistently replicated findings in cardiovascular nutrition. A pooled analysis of 10 large cohort studies estimated that people with an Omega-3 Index between 4% and 8% had about 30% lower risk of dying from coronary heart disease compared to those below 4%. In the Framingham Offspring cohort, people in the top fifth of omega-3 levels (above 6.8%) had about 39% lower risk of any new cardiovascular event compared to those in the bottom fifth (below 4.2%).
The protection appears to extend beyond just risk scores. In a randomized trial of 218 patients who already had coronary artery disease and were taking statins (cholesterol-lowering medications), those whose plasma (liquid portion of blood) omega-3 levels reached at least 4% showed no progression of arterial plaque over two years, while those below 4% continued to accumulate plaque. This suggests that omega-3 levels matter even when standard cholesterol treatment is already in place.
One concern that sometimes surfaces is whether high omega-3 levels might trigger atrial fibrillation (a type of irregular heartbeat). A large pooled analysis drawing on data from multiple cohorts found that higher habitual blood levels of EPA, DHA, and combined EPA plus DHA were not associated with increased atrial fibrillation risk. The atrial fibrillation signal seen in some high-dose prescription omega-3 trials does not appear to apply to the levels achieved through food and standard supplementation.
The mortality data is striking. A pooled analysis of 17 prospective studies found that higher circulating levels of marine omega-3 fatty acids were associated with lower risk of premature death from all major causes, including cardiovascular disease, cancer, and other conditions. A separate meta-analysis confirmed these associations, finding that higher levels of marine-derived omega-3 biomarkers (as opposed to plant-based omega-3s like ALA) were linked to reduced risk of cardiovascular disease, cancer, and overall mortality.
If your OmegaCheck result places you in the lowest tier, it signals a modifiable risk factor for early death that is entirely independent of your cholesterol numbers. Raising your levels into the target range is one of the few nutritional changes with this breadth of outcome data behind it.
Your brain is one of the most omega-3-dependent organs in your body. EPA and DHA are structural components of brain cell membranes, and blood levels of these fats track meaningfully with brain outcomes. Research reviews have linked lower EPA and DHA blood levels to increased risk of stroke, reduced brain volume on imaging, poorer cognitive performance, and higher rates of dementia.
Specific risk thresholds are beginning to emerge. In a study of 724 older adults without dementia, an Omega-3 Index below 5.3% was identified as the optimal cutoff for predicting who would experience cognitive decline over the following years. A narrative review of psychiatric research proposed risk thresholds of 4% to 5% for major depression and dementia, around 5% for postpartum depression, and 4% for transition to psychosis in high-risk individuals.
One caveat: while low omega-3 status clearly tracks with worse brain outcomes, supplementation trials have not consistently shown cognitive benefit. In the MAPT trial of 1,680 older adults with memory complaints, three years of omega-3 supplementation (800 mg DHA plus 225 mg EPA daily) did not significantly slow cognitive decline compared to placebo. This does not mean omega-3 levels are irrelevant to the brain. It may mean that supplementation started late in life, after damage has accumulated, cannot reverse what has already happened, making the case for knowing and optimizing your levels earlier rather than later.
A pooled analysis of 19 cohort studies found that higher blood levels of seafood-derived omega-3 fatty acids, including EPA, DPA (docosapentaenoic acid, another marine omega-3), and DHA, were associated with lower risk of developing chronic kidney disease. Plant-derived omega-3s (alpha-linolenic acid, or ALA, found in flaxseed and walnuts) showed no such association. If you are tracking kidney function through tests like eGFR (estimated glomerular filtration rate) or cystatin C, your omega-3 status adds a complementary piece of information about long-term kidney risk.
In a study of 1,119 community-dwelling Korean adults aged 70 to 84, those with higher red blood cell levels of EPA and DHA at baseline had significantly lower rates of frailty over a six-year follow-up. This finding fits a broader pattern: omega-3 status appears to be a marker of biological resilience that connects to outcomes across multiple organ systems, not just the heart.
The most widely used risk categories come from studies measuring the Omega-3 Index (EPA plus DHA as a percentage of total red blood cell fatty acids). Your OmegaCheck result is measured in whole blood, which correlates closely with the RBC-based Omega-3 Index but may report on a slightly different numerical scale depending on the lab method. Use these tiers as directional guidance, and always compare your results within the same lab over time for the most meaningful trend.
| Risk Tier | Omega-3 Index Range | What It Suggests |
|---|---|---|
| High risk | Below 4% | Associated with the highest rates of heart disease, early death, and cognitive decline in outcome studies. Raising your level should be a priority. |
| Intermediate | 4% to 8% | Lower risk than the bottom tier, but still below the target associated with the best outcomes. Room for improvement through diet or supplementation. |
| Optimal | 8% to 11% | The target range associated with the lowest cardiovascular and overall mortality risk. This is where you want to be. |
A cognitive decline study identified 5.3% as a meaningful cutoff: older adults below this level were at increased risk of cognitive decline, while those above it were relatively protected. For psychiatric risk, thresholds of 4% to 5% have been proposed for depression and dementia. These reinforce the general principle that levels below 4% to 5% carry meaningfully higher risk across multiple organ systems.
Compare your results within the same lab over time rather than treating any single threshold as absolute. Different labs use different analytical methods, and small technical differences can shift your number. The trend matters more than any individual reading.
Because OmegaCheck reflects your omega-3 status over weeks to months (not hours), it is one of the more stable blood tests you can order. A single meal or a skipped supplement dose will not meaningfully shift your result. That said, a few situations can distort the picture:
A single OmegaCheck result tells you where you stand today. A series of results over time tells you whether your diet, supplements, or other changes are actually working. Because the test reflects a two- to three-month average, the ideal tracking cadence is: get a baseline, make changes if needed, then retest in three to four months to see whether your levels have responded. Once you reach and maintain your target range, annual retesting is enough to confirm you are staying there.
This tracking approach is especially valuable if you are taking omega-3 supplements. Research consistently shows that people respond very differently to the same dose. In a dose-response trial of 115 healthy adults, body weight was a significant determinant of how much omega-3 reached red blood cells at any given dose. Heavier individuals needed higher doses to achieve the same Omega-3 Index. Without retesting, you have no way to know whether your current dose is actually enough for your body.
If your OmegaCheck result is in the high-risk range (roughly corresponding to an Omega-3 Index below 4%), treat it as a clear signal to act. Increase your intake of EPA and DHA through fatty fish (salmon, sardines, mackerel, anchovies) or a quality fish oil or algae supplement providing at least 1,000 to 1,500 mg of combined EPA and DHA daily. Research suggests this dose range, sustained for at least 12 weeks, is generally sufficient to move the needle meaningfully. Retest in three to four months to confirm your levels have responded.
If you are in the intermediate range (4% to 8%), you are in better shape but still below the target associated with the best outcomes. A modest increase in fish intake or supplementation, followed by retesting, can help you close the gap.
Regardless of your result, pairing OmegaCheck with a standard lipid panel, hs-CRP (high-sensitivity C-reactive protein, a measure of inflammation), and basic metabolic markers gives you a much fuller picture of your cardiovascular risk than any single test. If your omega-3 levels are low and your hs-CRP is elevated, the combination suggests an inflammatory environment that deserves attention. If your omega-3 levels are low despite consistent supplementation, consider whether your supplement form (triglyceride-based fish oil is generally better absorbed than ethyl ester forms), dose, or absorption may be the problem, and discuss it with a physician or lipid specialist.
Evidence-backed interventions that affect your OmegaCheck level
OmegaCheck is best interpreted alongside these tests.